Promising, already FDA-approved drugs were identified to reduce β-catenin-mediated S100A4 gene transcription resulting in diminished cellular motility in vitro and metastasis formation in vivo and are currently evaluated in clinical trials to reduce the risk of metastasis formation in CRC thereby improving patient survival and quality of life. Here, S100A4 is linked to colorectal carcinoma.